What Does Elevated Troponin Mean in COVID-19?

Allan Jaffe

The Protein Myth: Our Obsession With Protein and How It Is Killing US

Houston Methodist

G. Davis

Ambulatory Blood Pressure Monitoring

William White

Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Cardiac CT in 2023: From Anatomy to Physiology to Plaque Burden and …

Michael Gallagher

AHA 2022: Chlorthalidone Compared to Hydrochlorothiazide for the Pre…

AHA 2022 Conference Coverage

A. Ishani

Health of Vegetarians and Vegans: Findings From EPIC-Oxford and Othe…

Physicians Committee for Responsible Medicine

T. J. Key

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

ACC 2022: Triple Therapy - When to Use and How Long

ACC 2022 Conference Coverage

D. Kumbhani

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Is There a Future for HbA1c? (Moving Towards CGM: GMI and TIR)

Practical Ways to Achieve Targets in Diabetes Care

I. Hirsch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan